Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1971 1
1978 1
1979 3
1980 2
1981 1
1982 2
1983 3
1984 5
1985 2
1986 2
1987 6
1988 7
1989 9
1990 5
1991 11
1992 14
1993 11
1994 17
1995 12
1996 14
1997 25
1998 17
1999 27
2000 23
2001 32
2002 23
2003 25
2004 25
2005 26
2006 30
2007 36
2008 47
2009 60
2010 49
2011 75
2012 90
2013 107
2014 128
2015 147
2016 153
2017 133
2018 135
2019 153
2020 162
2021 165
2022 186
2023 166
2024 87

Text availability

Article attribute

Article type

Publication date

Search Results

2,114 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Thoracic Esophagus Squamous Cell Carcinoma"
Page 1
Update on Management of Squamous Cell Esophageal Cancer.
Waters JK, Reznik SI. Waters JK, et al. Curr Oncol Rep. 2022 Mar;24(3):375-385. doi: 10.1007/s11912-021-01153-4. Epub 2022 Feb 10. Curr Oncol Rep. 2022. PMID: 35142974 Review.
Squamous cell carcinoma of the esophagus (ESCC) is the predominant histologic type in the world. ...This review will summarize the epidemiology, diagnosis, staging, and treatment of esophageal squamous cell carcinoma. RECENT …
Squamous cell carcinoma of the esophagus (ESCC) is the predominant histologic type in the world. ...This review …
Esophagus cancer and essential trace elements.
Yang X, Tang Z, Li J, Jiang J. Yang X, et al. Front Public Health. 2022 Nov 16;10:1038153. doi: 10.3389/fpubh.2022.1038153. eCollection 2022. Front Public Health. 2022. PMID: 36466456 Free PMC article. Review.
Some essential trace elements could play a vital role in preventing esophagus cancer. Some showed no association with esophageal cancer risk, while others harmed individuals. This article reviews the association between the intake or supplementation of essential tra …
Some essential trace elements could play a vital role in preventing esophagus cancer. Some showed no association with esophageal …
A fibroblast-associated signature predicts prognosis and immunotherapy in esophageal squamous cell cancer.
Ren Q, Zhang P, Zhang X, Feng Y, Li L, Lin H, Yu Y. Ren Q, et al. Front Immunol. 2023 May 29;14:1199040. doi: 10.3389/fimmu.2023.1199040. eCollection 2023. Front Immunol. 2023. PMID: 37313409 Free PMC article.
Cancer-associated fibroblasts (CAFs) has been identified significantly correlated with tumor progression and therapy resistance. Thus, we aimed to probe into the CAFs characteristics in esophageal squamous cancer (ESCC) and construct a risk signature based on CAFs t …
Cancer-associated fibroblasts (CAFs) has been identified significantly correlated with tumor progression and therapy resistance. Thus, we ai …
Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial.
Tang H, Wang H, Fang Y, Zhu JY, Yin J, Shen YX, Zeng ZC, Jiang DX, Hou YY, Du M, Lian CH, Zhao Q, Jiang HJ, Gong L, Li ZG, Liu J, Xie DY, Li WF, Chen C, Zheng B, Chen KN, Dai L, Liao YD, Li K, Li HC, Zhao NQ, Tan LJ. Tang H, et al. Ann Oncol. 2023 Feb;34(2):163-172. doi: 10.1016/j.annonc.2022.10.508. Epub 2022 Nov 15. Ann Oncol. 2023. PMID: 36400384 Free article. Clinical Trial.
BACKGROUND: Neoadjuvant therapy is recommended for locally advanced esophageal cancer, but the optimal strategy remains unclear. We aimed to evaluate the safety and efficacy of neoadjuvant chemoradiotherapy (nCRT) versus neoadjuvant chemotherapy (nCT) followed by minimally …
BACKGROUND: Neoadjuvant therapy is recommended for locally advanced esophageal cancer, but the optimal strategy remains unclear. We a …
A multi-omics study delineates new molecular features and therapeutic targets for esophageal squamous cell carcinoma.
Jin X, Liu L, Wu J, Jin X, Yu G, Jia L, Wang F, Shi M, Lu H, Liu J, Liu D, Yang J, Li H, Ni Y, Luo Q, Jia W, Wang W, Chen WL. Jin X, et al. Clin Transl Med. 2021 Sep;11(9):e538. doi: 10.1002/ctm2.538. Clin Transl Med. 2021. PMID: 34586744 Free PMC article.
Esophageal squamous cell carcinoma (ESCC) is a major histological subtype of esophageal cancer with inferior prognosis. ...Among these prognostic proteins, only FBL, a well-known nucleolar methyltransferase, was essential for ESCC cell gr …
Esophageal squamous cell carcinoma (ESCC) is a major histological subtype of esophageal cancer with infer …
First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial.
Song Y, Zhang B, Xin D, Kou X, Tan Z, Zhang S, Sun M, Zhou J, Fan M, Zhang M, Song Y, Li S, Yuan Y, Zhuang W, Zhang J, Zhang L, Jiang H, Gu K, Ye H, Ke Y, Li J, Wang Q, Zhu J, Huang J; ASTRUM-007 investigators. Song Y, et al. Nat Med. 2023 Feb;29(2):473-482. doi: 10.1038/s41591-022-02179-2. Epub 2023 Feb 2. Nat Med. 2023. PMID: 36732627 Free PMC article. Clinical Trial.
First-line systemic therapeutic options for advanced esophageal squamous cell carcinoma (ESCC) are limited. In this multicenter, double-blind phase 3 trial, a total of 551 patients with previously untreated, locally advanced or metastatic ESCC and PD-L …
First-line systemic therapeutic options for advanced esophageal squamous cell carcinoma (ESCC) are limited. In t …
Salivary Extracellular MicroRNAs for Early Detection and Prognostication of Esophageal Cancer: A Clinical Study.
Li K, Lin Y, Zhou Y, Xiong X, Wang L, Li J, Zhou F, Guo Y, Chen S, Chen Y, Tang H, Qiu X, Cai S, Zhang D, Bremer E, Jim Yeung SC, Zhang H. Li K, et al. Gastroenterology. 2023 Oct;165(4):932-945.e9. doi: 10.1053/j.gastro.2023.06.021. Epub 2023 Jul 1. Gastroenterology. 2023. PMID: 37399999 Free article.
BACKGROUND & AIMS: Early detection of esophageal squamous cell carcinoma (ESCC) will facilitate curative treatment. ...Because 1 was not always detectable in the discovery cohort and cell lines, the other 6 miRNAs formed a panel. A signature …
BACKGROUND & AIMS: Early detection of esophageal squamous cell carcinoma (ESCC) will facilitate curative tre …
Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Guo W, Tan F, Huai Q, Wang Z, Shao F, Zhang G, Yang Z, Li R, Xue Q, Gao S, He J. Guo W, et al. Front Immunol. 2021 May 12;12:669750. doi: 10.3389/fimmu.2021.669750. eCollection 2021. Front Immunol. 2021. PMID: 34054840 Free PMC article.
BACKGROUND: Esophageal squamous cell carcinoma (ESCC) is one of the most common cancer types and represents a threat to global public health. ...The m6A methylation regulator may be a key mediator of PD-L1 expression and immune cell infiltration …
BACKGROUND: Esophageal squamous cell carcinoma (ESCC) is one of the most common cancer types and represents a th …
Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma.
Yang W, Xing X, Yeung SJ, Wang S, Chen W, Bao Y, Wang F, Feng S, Peng F, Wang X, Chen S, He M, Zhang N, Wang H, Zeng B, Liu Z, Kidane B, Seder CW, Koyanagi K, Shargall Y, Luo H, Peng S, Cheng C. Yang W, et al. J Immunother Cancer. 2022 Jan;10(1):e003497. doi: 10.1136/jitc-2021-003497. J Immunother Cancer. 2022. PMID: 35022193 Free PMC article.
BACKGROUND: Programmed cell death 1 (PD-1) blockade induces tumor regression in patients with advanced esophageal squamous cell carcinoma (ESCC); however, little is known about the efficacy of PD-1 blockade as neoadjuvant therapy in resectable E …
BACKGROUND: Programmed cell death 1 (PD-1) blockade induces tumor regression in patients with advanced esophageal squamous …
High-dimensional single-cell proteomics analysis of esophageal squamous cell carcinoma reveals dynamic alterations of the tumor immune microenvironment after neoadjuvant therapy.
Han D, Han Y, Guo W, Wei W, Yang S, Xiang J, Che J, Zhu L, Hang J, van den Ende T, van Laarhoven HWM, Li B, Ye Y, Li H. Han D, et al. J Immunother Cancer. 2023 Nov 28;11(11):e007847. doi: 10.1136/jitc-2023-007847. J Immunother Cancer. 2023. PMID: 38016720 Free PMC article.
BACKGROUND: Dynamic alterations of the tumor immune microenvironment in esophageal squamous cell carcinoma (ESCC) after different neoadjuvant therapies were understudied. METHODS: We used mass cytometry with a 42-antibody panel for 6 adjacent normal …
BACKGROUND: Dynamic alterations of the tumor immune microenvironment in esophageal squamous cell carcinoma (ESCC …
2,114 results